Wani bincike daga Jami'ar Cincinnati School of Medicine a Cibiyar Ciwon daji ta Shekara-shekara akan Oncology na tiyata a Chicago a ranar 24 ga Maris, 2018 ya nuna cewa adjuvant ko ƙarin jiyya bayan aikin tiyata na nau'ikan ciwace-ciwacen ƙwayar cuta ba ya inganta ƙimar tsira ga marasa lafiya. Waɗannan binciken suna ba da zurfin haske game da zaɓuɓɓukan jiyya na waɗannan nau'ikan masu cutar kansa, kuma maiyuwa ba za su ƙara buƙatar maganin adjuvant ba, kula da ingancin rayuwa, da adana kuɗi.
A cikin wannan binciken, masu bincike sun yi amfani da bayanan ciwon daji na mataki na I zuwa III marasa lafiya tare da cire ampulla daga 1998 zuwa 2006 (masu fama da cutar kansa 5,298) a cikin Cibiyar Ciwon daji ta Kasa na Kwalejin Likitocin Amurka don kwatanta tiyata kawai (3,785), tiyata tare da marasa lafiya. tare da ƙarin chemotherapy (316) da waɗanda ake yi wa tiyata tare da ƙarin chemotherapy da radiotherapy (1,197) an bincika don rayuwa gabaɗaya.
29% (1,513) of patients who underwent surgical resection of ampullary ciwan kansa received adjuvant therapy. Adjuvant therapy is more commonly used in patients with stage III, lymph node tumors, and positive surgical margins. However, there was no significant difference in stage-specific survival rates among patients with stage I, II, or III receiving any treatment. Similarly, patients with lymph node tumors and positive surgical margins received no adjuvant survival benefit. This national analysis showed that even for patients with aggressive disease, the adjuvant treatment of surgically removed ampullary tumors did not show any survival benefit.
Saboda haka, ko da wane irin ciwon daji, duk wani ciwon daji da ya ci gaba, ya zama dole a kimanta nau'in ciwon daji da kuma bambance-bambancen su a matakin salula. Ta hanyar gwajin kwayoyin halitta ne kawai za mu iya tantance sauye-sauyen matakin kwayoyin halitta na marasa lafiya da jagorar madaidaicin magani. Binciken atlas na dandamali da yawa na Amurka (kamfanin magunguna na jagorar cutar kansa a cikin Amurka) ba zai iya yin nazarin kwayoyin cutar kansa kawai a matakin kwayoyin ba, har ma ya haɗa RNA da gano furotin don nazarin hanyoyin ƙwayoyin ƙwayoyin cuta masu yawa, gabaɗaya. kimanta halayen ƙari, kuma gabaɗaya jagorar maganin alamun cutar. Ana iya tuntuɓar ƙarin cikakkun bayanai akan hanyar sadarwa ta Oncologist ta Duniya.
